Clearly, a patient’s genomic data is quite privacy sensitive, as it may reveal intrinsic limitations that among others can have a negative influence on someone’s career, mortgage negotiations, social relations, etc. While, in fact, market competition among diagnostic software services is likely to foster the quality of personalized diagnosis, an open market of such services can be deemed safe only if patient privacy is safeguarded at the platform level.